rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2011-869rsp-1002Research ArticleСтатьиArticlesПоказатели эффективности препаратов для лечения остеопороза: снижение относительного и абсолютного рискаThe efficacy of drugs for the treatment of osteoporosis: reducing the relative and absolute risksEvstigneevaL PEvstigneevaL P-ЛеснякО. М.LesnyakOl'ga Mikhaylovnalesnyak@sky.ru <mailto:lesnyak@sky.ru>EvstigneyevaL PEvstigneyevaL P-ЛеснякО. М.LesnyakOlga Mikhailovnalesnyak@sky.ru <mailto:lesnyak@sky.ru>201115022011491№1 (2011)6265Copyright © Evstigneeva L.P., Лесняк О.М., Evstigneyeva L.P., Лесняк О.М., 20112011Evstigneeva L.P., Лесняк О.М., Evstigneyeva L.P., Лесняк О.М.Evstigneeva L.P., Lesnyak O.M., Evstigneyeva L.P., Lesnyak O.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/1002References<div><p>Black D.M., Cummings S.R., Karpf D.B. et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-41.</p><p>Black D.M., Delmas P.D., Eastell R. et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356(18): 1809-22.</p><p>Rossouw J.E., Anderson G.L., Prentice R.L. et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288(3): 321-33.</p><p>Reginster J.Y., Seeman E., De Vernejoul M.C. et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocr 2005; 90: 2816-22.</p><p>Власов В.В. Эпидемиология: Учеб. пособие для вузов. М.: ГЭОТАР-Мед, 2004; 464 с.</p><p>Остеопороз. Под ред. О.М. Лесняк, Л.И. Беневоленской. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2009; 272 с.</p><p>Chapuy М.С., Arlot М.Е., Delmas P.D., Meunier P.J. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. Brit Med J 1994; 308(6936): 1081-2.</p><p>Jackson R.D., LaCroix A.Z., Gass M. et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354(7): 669-83.</p><p>Meunier P.J., Roux C., Seeman E. et al. The effects of Strontium Ranelate on the risk of vertebral fracture in women with post- menopausal osteoporosis. N Engl J Med 2004; 350: 459-68.</p><p>Chesnut C.H. III, Skag A., Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19(8): 1241-9.</p><p>Chesnut C.H. III, Silverman S., Andriano K. et al. A randomized trial of nasal spray salmon calcitonin in post- menopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000; 109: 267-76.</p><p>Roux C., Reginster J.Y., Fechtenbaum J. Vertebral fracture risk reduction with strontium ranelate in women with post- menopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 2006; 21(4): 536-42.</p><p>Duehmke R.M., Hollingshead J., Cornblath D.R. Tramadol for neuropathic pain. Cochrane Database of Systematic Reviews 2006; Issue 3; Art. No.: CD003726. DOI:</p></div><br /><div><p>Black D.M., Cummings S.R., Karpf D.B. et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-41.</p><p>Black D.M., Delmas P.D., Eastell R. et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356(18): 1809-22.</p><p>Rossouw J.E., Anderson G.L., Prentice R.L. et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288(3): 321-33.</p><p>Reginster J.Y., Seeman E., De Vernejoul M.C. et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocr 2005; 90: 2816-22.</p><p>Власов В.В. Эпидемиология: Учеб. пособие для вузов. М.: ГЭОТАР-Мед, 2004; 464 с.</p><p>Остеопороз. Под ред. О.М. Лесняк, Л.И. Беневоленской. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2009; 272 с.</p><p>Chapuy М.С., Arlot М.Е., Delmas P.D., Meunier P.J. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. Brit Med J 1994; 308(6936): 1081-2.</p><p>Jackson R.D., LaCroix A.Z., Gass M. et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354(7): 669-83.</p><p>Meunier P.J., Roux C., Seeman E. et al. The effects of Strontium Ranelate on the risk of vertebral fracture in women with post- menopausal osteoporosis. N Engl J Med 2004; 350: 459-68.</p><p>Chesnut C.H. III, Skag A., Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19(8): 1241-9.</p><p>Chesnut C.H. III, Silverman S., Andriano K. et al. A randomized trial of nasal spray salmon calcitonin in post- menopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000; 109: 267-76.</p><p>Roux C., Reginster J.Y., Fechtenbaum J. Vertebral fracture risk reduction with strontium ranelate in women with post- menopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 2006; 21(4): 536-42.</p><p>Duehmke R.M., Hollingshead J., Cornblath D.R. Tramadol for neuropathic pain. Cochrane Database of Systematic Reviews 2006; Issue 3; Art. No.: CD003726. DOI:</p></div><br />
The authors declare that there are no conflicts of interest present.